http://www.whale.to/vaccine/mmr15.html
MMR
Urabe vaccine (Pluserix
& Immravax)
MMR
vaccines
On september 14, 1992 two
measles vaccines (Pluserix & Immravax) were banned in the UK after it was
revealed that children had developed meningitis. On Sept 16, 1992 the New
Zealand government withdrew Pluserix
"In 1990, scientists from the Queen’s
Medical Centre Nottingham found some children developed a form of meningitis
after receiving it. But despite this the Government went on using it for more
than two years. The Canadian Government, also using the vaccine,
immediately switched to a safer version. It was not until September 1992 that
the UK Department of Health issued pharmacists with emergency supplies of a
safer brand with instructions to withdraw existing batches."--Sunday Express
[Media UK, April 2001 MMR] Jab risk was ignored
1997 Brazil:
OUTBREAK OF ASEPTIC MENINGITIS ASSOCIATED WITH MASS
VACCINATION WITH A URABE CONTAINING MMR VACCINE
"When notifications of meningitis (from
MMR vaccine) from physicians were included; when the vaccine records of
hospital cases of meningitis were included; when cross linkage of vaccine
records from laboratory reports (4 laboratories) was performed and included the
figure was increased to 1 in 11,000. It should be noted that in the case of one
particular laboratory, this was 1 in 4,000. "----- Paul Shattock and Dawn
Savery, Autism Research Unit, University of Sunderland, Sunderland,
UK. The Role
of Vaccines in the Causation of Autism and Related Disorders---Paul Shattock
and Dawn Savery, Autism Research Unit, University of Sunderland, Sunderland,
UK.1997
"Out of the 90 children on that list, 24
received a vaccine called Pluserix-MMR manufactured by SmithKline Beecham. It
was withdrawn in the UK on the 14th September 1992 because of "reports of
mild transient meningitis." "Of the children that
received Pluserix-MMR on that list, 3 died (1 after meningitis) , 4 had
meningitis symptoms, 5 epilepsy, 5 had become autistic, 1 suffered from
rheumatoid arthritis, 1 had severe urticaria and 2 had mumps. 6 had their
speech affected - forgetting language skills they had acquired, 1 went deaf. 6
from this time suffered from delayed development and 4 were very very
disturbed. One of the deaths was from the Guillain-Barré syndrome - where
antibodies are produced that attack the body's own cells . 7 or more suffered
frequent fits or convulsions, 1 had terrible screaming fits. Thirteen of
the children on that list received Immravax made by the French company, Merieux
UK Ltd. This was also withdrawn on the same date and for the same reason as
Pluserix-MMR - because of "reports of mild transient meningitis.".
Of the children that received Immravax; 6 became epileptic, 1 nearly
died from encephalitis, 3 had meningitis, 1 measles and 1 mumps, 5 had speech
and communication problems, 3 became slow developers, 7 had frequent fits and
convulsions, 2 went into the kind of terrible screaming fits that are
associated with brain trauma."---Jani Roberts http://www.gn.apc.org/inquirer/jabs.html
"The Urabe strain, he writes, was
replaced here in 1992 after it was "rarely" associated with
"severe headaches". Actually the Urabe strain was used in the
MMR vaccines, Immravax and Pluserix, in this country between 1988 and 1992.
Both were hastily withdrawn in 1992 after they were found to cause not
"rare" but unusually high rates (more than I in 11,000) of
potentially fatal aseptic mumps meningitis— er, a little more than a
"severe headache", the Eye would suggest. And Watson should
know because his company, then Merieux UK, manufactured the dodgy Immravax.
Smith Kline Beecham produced the other.
And here are two more important "facts" he left
out. When those MMR vaccines were licensed here in 1988, an identical vaccine
containing the Urabe strain produced by Smith Kline Beecham and called Trivirex
had already been withdrawn from Canada because of suspected links to aseptic
mumps meningitis. This no doubt would have passed unnoticed by our government
scientists responsible for licensing because — as we now know courtesy of the
BSE inquiry — the department was then a shambles. But it could not have passed
unnoticed by MMR manufacturers.
Yet as late as 1997 the Smith Kline Beecham Urabe MMR jab
was used in a mass vaccination programme in Brazil and caused, yes, an outbreak
of aseptic meningitis."---Private
Eye
[Media
June 2000, MMR--meningitis & death] Mother’s regret over son who still
suffers
MMR vaccine & aseptic meningitis, Japan 1989-1993
Dourado I, Cunha S, Teixeira MG, Farrington CP, Melo
A, Lucena R, Barreto ML.Outbreak of
aseptic meningitis associated with mass vaccination with a urabe-containing
measles-mumps-rubella vaccine: implications for immunization programs. Am J
Epidemiol. 2000 Mar 1;151(5):524-30.
PMID: 10707922
A mass immunization campaign with a Urabe-containing measles-mumps-rubella
vaccine was carried out in 1997 in the city of Salvador, northeastern Brazil,
with a target population of children aged 1-11 years. There was an outbreak of
aseptic meningitis following the mass campaign. Cases of aseptic meningitis
were ascertained through data collected from the records of children admitted
to the local referral hospital for infectious diseases between March and
October of 1997, using previously defined eligibility criteria. Vaccination
histories were obtained through home visits or telephone calls. Eighty-seven
cases fulfilled the study criteria. Of those, 58 cases were diagnosed after the
vaccination campaign. An elevated risk of aseptic meningitis was observed 3
weeks after Brazil's national vaccination day compared with the risk in the
prevaccination period (relative risk = 14.3; 95% confidence interval: 7.9,
25.7). This result was confirmed by a case series analysis (relative risk =
30.4; 95% confidence interval: 11.5, 80.8). The estimated risk of aseptic
meningitis was 1 in 14,000 doses. This study confirms a link between
measles-mumps-rubella vaccination and aseptic meningitis. The authors discuss
the implications of this for the organization and planning of mass immunization
campaigns.
Autret
E, Jonville-Bera AP, Galy-Eyraud C, Hessel L.[Aseptic meningitis after
mumps vaccination].Therapie. 1996 Nov-Dec;51(6):681-3. French.PMID: 9164005
The aim of this retrospective study was to
evaluate the incidence and the characteristics of spontaneously reported
aseptic meningitis (AM) in France following mumps vaccination with monovalent
or multivalent vaccines containing the Urabe strain. Fifty-four cases of AM were
reported to the regional drug surveillance centres or to the manufacturer from
the time each vaccine was launched up until June 1992. Twenty cases were
associated with the time off administration of a monovalent mumps vaccine and
34 with a trivalent measles, mumps and rubella vaccine (MMR). A mumps virus was
isolated in four cases in the cerebrospinal fluid and an Urabe-like strain was
characterised twice by polymerase chain reaction (PCR). A probable mumps origin
was assumed in 17 other cases where the patients presented with other clinical
or biological signs of mumps infection. The clinical outcome of AM was always
favourable. The global incidence of mumps vaccine-associated AM was
0.82/100,000 doses, which is significantly lower than the incidence in the
unvaccinated population. Even considering that the actual incidence of AM is
much higher when assessed by active surveillance studies, the risk/benefit
ratio of mumps vaccine remains in favour of vaccination. The incidence of mumps
vaccines containing Jeryl Lynn (ROR Vax et Imu ORR) associated with AM needs to
be evaluated.
Kimura
M, Kuno-Sakai H, Yamazaki S, Yamada A, Hishiyama M, Kamiya H, Ueda K, Murase T,
Hirayama M, Oya A, Nozaki S, Murata R.Adverse events associated with MMR
vaccines in Japan. Acta Paediatr Jpn. 1996 Jun;38(3):205-11.PMID: 8741307
The largest nationwide active surveillance of four Measles-Mumps-Rubella (MMR)
vaccines was conducted in Japan. A total of 1255 pediatricians actively
participated in the study, which comprised 8.6% of all members of the Japanese
Pediatric Society. The total number of registered recipients of MMR vaccines
was 38 203. They were arbitrarily given one of the MMR vaccines produced by
three makers (Takeda, Osaka city, Kitasato Minato-ku. Tokyo and Biken Suita
city, Japan) or the standard MMR vaccine made of designated strains (Kitasato's
measles-AIK-C, Biken's mumps-Urabe Am9 and Takeda's rubella-To336) produced by
Takeda, Kitasato and Biken and were observed for 35 days. The rates of
virologically confirmed aseptic meningitis per 10,000 recipients were 16.6,
11.6, 3.2 and 0 for the standard MMR, Takeda MMR, Kitasato MMR and Biken MMR
vaccines, respectively. The incidence of convulsions between 15 and 35 days was
the highest with the standard MMR vaccine and the incidence of fever associated
with vomiting occurring between 15 and 35 days (symptoms relevant to aseptic
meningitis) were also the highest with the standard MMR vaccine. The incidence
of parotid swelling was the lowest with Takeda MMR vaccine. This surveillance
revealed that incidences of aseptic meningitis after administration of the
standard MMR vaccine and of Biken MMR vaccine were different. This posed
questions about the manufacturing consistency of the Urabe Am9 mumps virus
vaccines. On the other hand, the National Institute of Health found that the
biological characteristics of the Urabe Am9 mumps virus contained in the
standard MMR vaccine and in the Biken MMR vaccine were different. The Biken
Company reported that the mumps vaccine in the standard MMR vaccine was a
mixture of two Urabe Am9 mumps vaccine bulks; one identical to that contained
in the Biken MMR vaccine and the other produced by a different manufacturing
process. PMID: 8741307
[VaccineWebsite]
[MMR vaccines]
ALL
INFORMATION, DATA, AND MATERIAL CONTAINED, PRESENTED, OR PROVIDED HERE IS FOR
GENERAL INFORMATION PURPOSES ONLY AND IS NOT TO BE CONSTRUED AS REFLECTING THE
KNOWLEDGE OR OPINIONS OF THE PUBLISHER, AND IS NOT TO BE CONSTRUED OR INTENDED
AS PROVIDING MEDICAL OR LEGAL ADVICE. THE DECISION WHETHER OR NOT TO
VACCINATE IS AN IMPORTANT AND COMPLEX ISSUE AND SHOULD BE MADE BY YOU, AND YOU
ALONE, IN CONSULTATION WITH YOUR HEALTH CARE PROVIDER.